drugset / Trial / NCT07114939
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Phase 1
Recruiting
12 enrolled
Abramson Cancer Center at Penn Medicine
University of Pennsylvania · collab
NaSingle-groupOpen-labelDiagnostic
Summary
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]FluorThanatrace | Diagnostic / imaging agent | 10 unknown | Intravenous |